On the other hand, it has been seen that patients with chronic hepatitis C treated with PEGIFN+RBV and presenting an increase in IL-10 regulatory cytokine may actually compromise the host immune response [38]. This evidence concerns the gene IL10 and chronic hepatitis C virus infection.